Product Information
DOXAZOSIN MESYLATE 8 MG TAB is a generic product labeled by Mylan Pharmaceuticals Inc., priced at $0.0976 per EA under NDC 59762248007. Its NADAC has been published 249 times since Dec 29, 2021.
FDA first approved this application on Nov 2, 1990. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the doxazosin market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
8 mg/1
Manufacturer
Mylan Pharmaceuticals Inc.NDC
59762248007
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
DOXAZOSIN MESYLATEApproval Type
Authorized Generic (NDA)
FDA Application
NDA019668FDA Approved
11/2/1990
TE Code
AB
On Market Since
10/19/2021
Pharmacological Classes
Price Statistics
The NADAC for DOXAZOSIN MESYLATE 8 MG TAB has been published 249 times since Dec 29, 2021, and over the history we have for it it has declined 28.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0976 per EA |
|---|---|
| All-time high | $0.1500 (Feb 14, 2024) |
| All-time low | $0.0731 (Nov 20, 2024) |
| 52-week high | $0.1097 |
| 52-week low | $0.0965 |
| Median price | $0.1071 |
| Average price | $0.1076 |
| Largest weekly change | +33.1% (Feb 22, 2023) |
| Weeks tracked | 249 |
| Tracking since | Dec 29, 2021 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doxazosin market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Mylan Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxazosin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
alpha-Adrenergic Blocker class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXAZOSIN MESYLATE 8 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for DOXAZOSIN MESYLATE 8 MG TAB, manufactured by Mylan Pharmaceuticals Inc., is $0.0976 per EA (NDC 59762248007), effective Sep 30, 2026.
How has the price of DOXAZOSIN MESYLATE 8 MG TAB changed over time?
Over the history we have for it, the NADAC for DOXAZOSIN MESYLATE 8 MG TAB has declined 28.1%. It has been tracked across 249 weekly CMS publications since Dec 29, 2021.
What are the highest and lowest recorded NADAC prices for DOXAZOSIN MESYLATE 8 MG TAB?
Since Dec 29, 2021, the NADAC for DOXAZOSIN MESYLATE 8 MG TAB has ranged from a low of $0.0731 (Nov 20, 2024) to a high of $0.1500 (Feb 14, 2024), with a median of $0.1071 per EA.
Are there cheaper alternatives to DOXAZOSIN MESYLATE 8 MG TAB?
No other NADAC-published product currently shares the active ingredient and strength of DOXAZOSIN MESYLATE 8 MG TAB in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXAZOSIN MESYLATE 8 MG TAB?
DOXAZOSIN MESYLATE 8 MG TAB (NDC 59762248007) is labeled by Mylan Pharmaceuticals Inc., and CMS classifies it as a generic product.